Multiplex Engineering of Human CD34+ HSPCs Enables Dual Gene Knockout While Maintaining High Engraftment Potential and Safety […]
Read More… from ASH Annual Meeting 2021 – Poster Presentation 2939
Multiplex Engineering of Human CD34+ HSPCs Enables Dual Gene Knockout While Maintaining High Engraftment Potential and Safety […]
Read More… from ASH Annual Meeting 2021 – Poster Presentation 2939
Knock Out of CD123 or CLL-1 by CRISPR-Cas9 Editing From Human Hematopoietic Stem Cell Transplantations Provide New Possibilities for Increasing Therapeutic Index and Safety for AML Treatment […]
Read More… from ASH Annual Meeting 2021 – Poster Presentation 3818
An NFAT Promoter–Based Fluorescent Jurkat Cell Platform for High- Throughput Screening of Chimeric Antigen Receptor (CAR) Constructs […]
Construction and Evaluation of Interleukin 3 (IL3)-Zetakine–Redirected Cytolytic T Cells for Treatment of CD123-Expressing Acute Myeloid Leukemia […]
In Depth Assessment of Off-target Editing by CRISPR/Cas9 in VOR33, an Engineered Hematopoietic Stem Cell Transplant for the Treatment of Acute Myeloid Leukemia […]
VOR33: A Clinic-Ready CRISPR/Cas9 Engineered Hematopoietic Stem Cell Transplant for the Treatment of Acute Myeloid Leukemia […]
VOR33: A Clinic-Ready CRISPR/Cas9 Engineered Hematopoietic Stem Cell Transplant for the Treatment of Acute Myeloid Leukemia […]
Rigorous Assessment of Off-Target Editing by CRISPR/Cas9 in VOR33, an Engineered Hematopoietic Stem Cell Transplant for the Treatment of Acute Myeloid Leukemia […]